This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.90% per year. These returns cover a period from January 1, 1988 through December 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Celcuity Stock Up 677% in 6 Months: What's Behind This Huge Increase?
by Zacks Equity Research
CELC shares surge as NDA filing and strong phase III data boost optimism around gedatolisib's potential.
FOLDNo Net Change ANIPPositive Net Change CRMDNegative Net Change CELCNegative Net Change
biotechs
ANIP Up 21% in 6 Months: Is It Worth Investing in the Stock Now?
by Sundeep Ganoria
ANI Pharmaceuticals' shares are up 21% in six months as strong 2025 results, repeated earnings beats and higher guidance highlight momentum in rare diseases.
TEVAPositive Net Change ANIPPositive Net Change AMRXPositive Net Change
biotechs medical
ZBIO Tanks Despite Positive Data From Rare Autoimmune Diseases Study
by Zacks Equity Research
Zenas BioPharma tanks nearly 52% despite positive INDIGO study data where obexelimab cut IgG4-RD flare risk by 56% and met all key endpoints.
ANIPPositive Net Change CRMDNegative Net Change EXASNo Net Change ZBIOPositive Net Change
biotechs
Will Galafold Be Able to Aid FOLD's Top Line Heading Into Q4 Earnings?
by Kanishka Das
Galafold drives over 80% of Amicus product revenues, with $371.5M in the first nine months of 2025 sales as investors await Q4 sales performance.
SNYNegative Net Change TEVAPositive Net Change FOLDNo Net Change
biotechs
MRNA Stock Jumps on Global Submissions Seeking Nod for Flu Vaccine
by Zacks Equity Research
Moderna jumps after filings seeking approval for its mRNA-1010 flu vaccine across major markets, with plans to launch the shot for older adults next year.
SNYNegative Net Change GSKPositive Net Change MRNANegative Net Change
biotechs medical messenger-rna vaccines
INCY's Phase III Monjuvi Study Meets Key Goals in First-Line Lymphoma
by Zacks Equity Research
Incyte's phase III study of Monjuvi combo for first-line DLBCL treatment met primary and key secondary goals, paving the way for a 2026 FDA filing.
BMYNegative Net Change INCYNegative Net Change ANIPPositive Net Change CRMDNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can the US Launch of NVO's Wegovy Pill Reignite Momentum in 2026?
by Ahan Chakraborty
Novo Nordisk shares jump after the U.S. launch of its FDA-approved Wegovy pill, giving the first oral GLP-1 weight-loss drug a chance to revive 2026 momentum.
NVOPositive Net Change LLYPositive Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Three Genomics Stocks Worth Tracking This Year
by Ekta Bagri
Genomics advances are reshaping drug discovery, with Pacific Biosciences of California emerging as a key player in next-gen sequencing.
ILMNPositive Net Change BEAMPositive Net Change PACBPositive Net Change WVEPositive Net Change CRSPPositive Net Change SANANegative Net Change
biotechnology biotechs cell-therapy gene-therapy genetics genomics medical pharmaceuticals thematic
KYMR Skyrockets 82.4% in a Year: More Upside Potential in 2026?
by Zacks Equity Research
KYMR rallied 82% in a year as KT-621 delivered strong phase Ib BroADen data and earned FDA Fast Track for atopic dermatitis.
REGNNegative Net Change SNYNegative Net Change GILDNegative Net Change KYMRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Intellia Stock Declines Around 55% in 3 Months: Here's Why
by Zacks Equity Research
NTLA shares plunge 55% in three months after the FDA placed a clinical hold on Nex-Z, suspending trials and milestone guidance following the death of a patient.
REGNNegative Net Change ANIPPositive Net Change CRMDNegative Net Change NTLAPositive Net Change
biotechs
FDA Accepts SNY Filing for Expanded Use of T1D Drug in Young Children
by Zacks Equity Research
Sanofi wins FDA priority review to expand Tzield's use to children as young as one, aiming to delay type 1 diabetes progression.
SNYNegative Net Change ANIPPositive Net Change CRMDNegative Net Change MGNXNegative Net Change
biotechs medical pharmaceuticals
Will NVO's Wegovy Pill Approval for Obesity be a Game Changer in 2026?
by Ahan Chakraborty
Novo Nordisk's FDA-approved Wegovy pill marks the first oral GLP-1 weight loss therapy, aiming to revive momentum and reshape competition in 2026.
NVOPositive Net Change LLYPositive Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
AXSM Up on FDA Priority Review to AXS-05 sNDA in Alzheimer's Agitation
by Zacks Equity Research
Axsome stock jumps as the FDA grants priority review to sNDA for AXS-05 in Alzheimer's agitation, with a decision expected April 30, 2026.
ANIPPositive Net Change CRMDNegative Net Change AXSMPositive Net Change CSTLNegative Net Change
biotechs
Will ANIP's Rare Disease Franchise Maintain Momentum in 2026?
by Ekta Bagri
ANIP's rare disease push, led by Cortrophin Gel, drove 70% sales growth in the first nine months of 2025, lifting revenue outlook.
REGNNegative Net Change ABBVNegative Net Change ANIPPositive Net Change
biotechnology biotechs medical pharmaceuticals
Here's How VKTX's Obesity Drug Is Moving Quickly Through Phase III
by Sundeep Ganoria
Viking Therapeutics' obesity drug VK2735 is racing through phase III, with one pivotal study fully enrolled just months after launch.
NVOPositive Net Change LLYPositive Net Change VKTXNegative Net Change
biotechs medical pharmaceuticals
REGN Soars 41% in Six Months: Is There More Upside Potential in 2026?
by Zacks Equity Research
Regeneron shares are up 41% in six months as FDA approvals, strong Dupixent profits and oncology gains lift investor confidence.
REGNNegative Net Change SNYNegative Net Change RHHBYPositive Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals
INSM Stock Up 78% in 6 Months: Here's What You Need to Know
by Zacks Equity Research
Insmed shares surged on FDA and EU approvals of Brinsupri, strong uptake, and a growing pipeline which fueled optimism around its revenue outlook.
INSMNegative Net Change ANIPPositive Net Change CRMDNegative Net Change CSTLNegative Net Change
biotechs
Here's How AbbVie's Neuroscience Portfolio Is Aiding Top-line Growth
by Sundeep Ganoria
ABBV's neuroscience franchise now drives more than 17% of revenues, with strong Botox, Vraylar and migraine drug sales fueling double-digit growth.
BIIBNegative Net Change JNJPositive Net Change ABBVNegative Net Change
biotechs medical pharmaceuticals
Here's Why Replimune Stock Skyrockets Nearly 131% in 3 Months
by Zacks Equity Research
REPL shares soar 131.1% over the past three months after the FDA accepts its resubmitted BLA for the RP1/Opdivo combo in advanced melanoma.
BMYNegative Net Change ANIPPositive Net Change CRMDNegative Net Change REPLPositive Net Change
biotechs
RARE Rises on Completion of Rolling Submission for AAV Gene Therapy
by Zacks Equity Research
Ultragenyx jumps after completing rolling BLA submission to the FDA for DTX401, an AAV gene therapy that could become the first approved treatment for GSDIa.
ANIPPositive Net Change RAREPositive Net Change CRMDNegative Net Change CSTLNegative Net Change
biotechs
Can BEAM's Gene Editing Pipeline Create Long-Term Value Amid Rivalry?
by Kanishka Das
Beam Therapeutics advances base-editing pipeline with risto-cel studies and FDA designations, but no approved products and rising competition loom.
BEAMPositive Net Change NTLAPositive Net Change CRSPPositive Net Change
biotechs
VNDA Obtains FDA Nod for Motion Sickness Drug, Stock Gains
by Zacks Equity Research
Vanda stock jumps after FDA approves tradipitant as Nereus for motion sickness, marking the first new therapy in over 40 years and boosting investor optimism.
NVOPositive Net Change VNDANegative Net Change ANIPPositive Net Change CRMDNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can BMY's Growth Portfolio Drive Top-Line Expansion in 2026?
by Ekta Bagri
Bristol Myers Squibb's growth drugs rose 17% in the first nine months of 2025, helping offset a 16% legacy drug sales decline.
BMYNegative Net Change PFENegative Net Change MRKNegative Net Change
biotechnology biotechs medical pharmaceuticals
BMY vs AMGN: Which Biotech Stock Is More Resilient Now?
by Ekta Bagri
AMGN edges out its rival with stronger growth estimates, a broad portfolio boost from Horizon, and momentum from key drugs like Repatha and Tezspire.
BMYNegative Net Change PFENegative Net Change MRKNegative Net Change AMGNNegative Net Change
biotechnology biotechs dividend-yield medical pharmaceuticals
Can Amgen's MariTide Take on Leaders in the Obesity Space?
by Zacks Equity Research
AMGN's MariTide enters late-stage obesity trials with monthly dosing but faces rising competition as Eli Lilly and Novo Nordisk push oral GLP-1s.
NVOPositive Net Change LLYPositive Net Change AMGNNegative Net Change
biotechs medical pharmaceuticals